Sandoz has struck a deal with Samsung Bioepis to partner on up to five biosimilars, with the first being SB36, a copycat of Takeda’s Entyvio (vedolizumab), which is being developed by the South ...
Sandoz has partnered with Samsung Bioepis to broaden patient access to high-quality biosimilar medicines worldwide. The ...
This agreement enables Samsung Bioepis to launch Opuviz 2 mg in the United States starting in January 2027. Choi MacDonald continued, "We are well-positioned to successfully launch our aflibercept ...
Please provide your email address to receive an email when new articles are posted on . Samsung Bioepis can launch Opuviz in the U.S. in January 2027. Opuviz, a biosimilar to Eylea, received FDA ...
Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's blockbuster drug Stelara, also known as ustekinumab. The drug is used to ...
The MarketWatch News Department was not involved in the creation of this content. -- The agreement covers up to five assets, including SB36, a biosimilar candidate referencing Entyvio (vedolizumab), ...
JERSEY CITY, N.J. & INCHEON, Korea--(BUSINESS WIRE)--Organon & Co. (NYSE: OGN) & Samsung Bioepis Co., Ltd. today announced that HADLIMA™ (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab) ...
The first asset will be a vedolizumab biosimilar to Entyvio used to treat adult patients with Crohn’s disease, ulcerative ...
The agreement covers up to five assets, including SB36, a biosimilar candidate referencing Entyvio (vedolizumab), for collaboration of development and commercialization in global markets excluding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results